Compare IZM & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IZM | JAGX |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0M | 5.0M |
| IPO Year | 2021 | 2014 |
| Metric | IZM | JAGX |
|---|---|---|
| Price | $0.39 | $3.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | 138.3K | ★ 320.3K |
| Earning Date | 10-24-2025 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,511,000.00 |
| Revenue This Year | N/A | $61.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.39 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.31 | $0.22 |
| 52 Week High | $2.74 | $8.00 |
| Indicator | IZM | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 44.98 | 63.47 |
| Support Level | $0.35 | $1.12 |
| Resistance Level | $0.99 | $8.00 |
| Average True Range (ATR) | 0.04 | 0.75 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 56.74 | 47.82 |
ICZOOM Group Inc. operates an e-commerce platform selling electronic components to SMEs in China across consumer electronics, IoT, automotive, and industrial control sectors. It offers two main product categories: semiconductor products, including integrated circuits and optoelectronics, and electronic equipment and tools such as electromechanical and MRO supplies. The company also provides services like customs clearance, temporary warehousing, and logistics, earning additional commission fees. The majority of its revenue comes from electronic component sales.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.